Compare Manhattan Associates Inc (MANH) vs Teladoc Health Inc (TDOC) Price & Performance

MANH is trading at $192.63, down 1.56% on the day, with a bullish technical outlook supported by moving averages and strong momentum indicators. The company reported robust Q2 2026 earnings, beating EPS estimates with $1.39 versus $1.32 expected, driven by 26% cloud revenue growth. However, valuation ratios remain elevated with a P/E of 55.93 and P/B of 72.26, indicating high investor expectations. Recent news highlights an ongoing legal investigation into fiduciary duties by the Rosen Law Firm, creating a mixed sentiment backdrop.

The outlook for MANH is cautiously optimistic, with a consensus price target of $210.33 offering 9.2% upside potential. Key opportunities include sustained cloud growth and strong profitability metrics like a 96.38% ROE. Risks involve the high valuation, potential legal overhangs from the investigation, and any slowdown in enterprise software demand. Institutional analysts maintain an 80% buy rating, suggesting confidence in execution despite near-term headwinds.

Teladoc Health (TDOC) trades at $6.62, down 6.5% on the day, reflecting investor concern after a Q2 2026 revenue miss and lowered full-year guidance. The stock is technically bearish with key support at $6, while fundamentals show revenue of $2.53B in 2025 but persistent net losses, with a negative net income margin of -7.13%. Recent news highlights multiple law firm investigations into the company following its guidance cut.

The outlook remains challenging due to weak BetterHelp performance and ongoing losses, though valuation ratios like P/S of 0.49 and EV/EBITDA of 6.96 suggest potential undervaluation. Risks include competitive pressures and legal scrutiny, but analyst consensus price target of $8.88 implies upside if execution improves.